MedTrace Logo

Semaglutide and Physical Activity for Obesity and Multimorbidity

NCT06234111 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2024-12-12

No results posted yet for this study

Summary

The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients with severe obesity and multimorbidity.

This study is explorative and therefore does not include hypothesis testing.

Conditions

  • Obesity Morbid
  • Multimorbidity
  • Obesity

Interventions

COMBINATION_PRODUCT

Semaglutide 2.4 mg, total diet replacement, behavioural intervention

Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Rasmus H Brødsgaard, MSc · Copenhagen University Hospital, Hvidovre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-20
Primary Completion
2026-10-31
Completion
2026-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06234111 on ClinicalTrials.gov